Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 18/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.58 |
| ▸ | SPR | P35270 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586043 | 1.00 | HCRTR1 (0.58) | HCRTR1HCRTR2SPRCYP1A2KCNH2 | |
| SCHEMBL1586870 | 0.85 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL1586869 | 0.85 | HCRTR1 (0.59) | HCRTR1HCRTR2 | |
| SCHEMBL9957752 | 0.79 | HCRTR2 (0.59) | HCRTR1HCRTR2SPR | |
| SCHEMBL6909460 | 0.78 | HCRTR1 (0.54) | HCRTR1HCRTR2 | |
| SCHEMBL1586756 | 0.76 | HCRTR1 (0.71) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL1586112 | 0.76 | HCRTR1 (0.52) | HCRTR1HCRTR2SPR | |
| SCHEMBL1586051 | 0.76 | HCRTR1 (0.52) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL14973550 | 0.76 | HCRTR1 (0.52) | HCRTR1HCRTR2CYP1A2KCNH2 | |
| SCHEMBL14983153 | 0.75 | HCRTR1 (0.58) | HCRTR1HCRTR2CYP1A2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062044-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| EP-2491031-B1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-08-07 | — | — | EP | disclosed |
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2013-05-30 | — | — | US | disclosed |
| EP-2491031-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137672-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885SPR 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.